RESUMO
Cancer-related pain is considered one of the most prevalent symptoms for those affected by cancer, significantly influencing quality of life and treatment outcomes. Morphine is currently employed for analgesic treatment in this case, however, chronic use of this opioid is limited by the development of analgesic tolerance and adverse effects, such as digestive and neurological disorders. Alternative therapies, such as ion channel blockade, are explored. The toxin Phα1ß has demonstrated efficacy in blocking calcium channels, making it a potential candidate for alleviating cancer-related pain. This study aims to assess the antinociceptive effects resulting from intravenous administration of the recombinant form of Phα1ß (r-Phα1ß) in an experimental model of cancer-related pain in mice, tolerant or not to morphine. The model of cancer-induced pain was used to evaluate these effects, with the injection of B16F10 cells, followed by the administration of the r-Phα1ß, and evaluation of the mechanical threshold by the von Frey test. Also, adverse effects were assessed using a score scale, the rotarod, and open field tests. Results indicate that the administration of r-Phα1ß provoked antinociception in animals with cancer-induced mechanical hyperalgesia, with or without morphine tolerance. Previous administration of r-Phα1ß was able to recover the analgesic activity of morphine in animals tolerant to this opioid. r-Phα1ß was proved safe for these parameters, as no adverse effects related to motor and behavioral activity were observed following intravenous administration. This study suggests that the concomitant use of morphine and r-Phα1ß could be a viable strategy for pain modulation in cancer patients.
Assuntos
Administração Intravenosa , Dor do Câncer , Tolerância a Medicamentos , Morfina , Animais , Morfina/administração & dosagem , Morfina/uso terapêutico , Morfina/farmacologia , Dor do Câncer/tratamento farmacológico , Camundongos , Analgésicos/uso terapêutico , Analgésicos/farmacologia , Venenos de Aranha , Analgésicos Opioides/uso terapêutico , Analgésicos Opioides/administração & dosagem , Masculino , Proteínas Recombinantes/uso terapêutico , Modelos Animais de Doenças , Hiperalgesia/tratamento farmacológicoRESUMO
Pain caused by the tumor or aromatase inhibitors (AIs) is a disabling symptom in breast cancer survivors. Their mechanisms are unclear, but pro-algesic and inflammatory mediators seem to be involved. Kinins are endogenous algogenic mediators associated with various painful conditions via B1 and B2 receptor activation, including chemotherapy-induced pain and breast cancer proliferation. We investigate the involvement of the kinin B1 and B2 receptors in metastatic breast tumor (4T1 breast cancer cells)-caused pain and in aromatase inhibitors (anastrozole or letrozole) therapy-associated pain. A protocol associating the tumor and antineoplastic therapy was also performed. Kinin receptors' role was investigated via pharmacological antagonism, receptors protein expression, and kinin levels. Mechanical and cold allodynia and muscle strength were evaluated. AIs and breast tumor increased kinin receptors expression, and tumor also increased kinin levels. AIs caused mechanical allodynia and reduced the muscle strength of mice. Kinin B1 (DALBk) and B2 (Icatibant) receptor antagonists attenuated these effects and reduced breast tumor-induced mechanical and cold allodynia. AIs or paclitaxel enhanced breast tumor-induced mechanical hypersensitivity, while DALBk and Icatibant prevented this increase. Antagonists did not interfere with paclitaxel's cytotoxic action in vitro. Thus, kinin B1 or B2 receptors can be a potential target for treating the pain caused by metastatic breast tumor and their antineoplastic therapy.
Assuntos
Antineoplásicos , Dor do Câncer , Neoplasias , Camundongos , Animais , Inibidores da Aromatase/farmacologia , Inibidores da Aromatase/uso terapêutico , Hiperalgesia/tratamento farmacológico , Hiperalgesia/metabolismo , Receptor B2 da Bradicinina/metabolismo , Receptor B1 da Bradicinina/metabolismo , Bradicinina/farmacologia , Dor , PaclitaxelRESUMO
Micrurus surinamensis is a semi-aquatic coral snake found in primary forest region and can cause relevant human accidents. In this work we investigated the toxic and antigenic activities of the Peruvian Micrurus surinamensis venom (MsV). We found that MsV show hyaluronidase activity but lack LAAO and PLA2 enzymatic activities. Interestingly, MsV induce edematogenic responses but cannot cause nociceptive effects. Furthermore, MsV can reduce in vitro cell viability in MGSO-3 cell line derived from human breast cancer tissue. To evaluate its antigenic potential, rabbits were immunized with MsV, which proved to be immunogenic. ELISA, immunobloting and in vivo neutralization assays demonstrated that the specific rabbit anti-MsV antivenom is more efficient than the therapeutic Brazilian antivenom in recognizing and neutralizing the lethal activity of MsV. MsV differs in protein profile and biological activities from M. frontalis venom (MfV), used as control, which impairs its recognition and neutralization by Brazilian therapeutic anti-elapidic antivenom. We performed a SPOT immunoassay for the identification of B-cell linear epitopes in the main toxins described for MsV targeted by the elicited neutralizing antibodies previously produced. A membrane containing 15-mer peptides representing the sequences of five 3TFxs and five PLA2s was produced and probed with anti- MsV antibodies. Results revealed important regions in 3FTx toxins for venom neutralization. Identifying the main MsV components and its biological activities can be helpful in guiding the production of antivenoms and in the optimization of treatment for coral snake envenomation in Brazil.
Assuntos
Cobras Corais , Toxinas Biológicas , Animais , Coelhos , Humanos , Antivenenos/farmacologia , Peru , Venenos Elapídicos/química , Toxinas Biológicas/química , ElapidaeRESUMO
Preservative treatments increase the durability of wood, and one of the alternative treatments involves the use of chromated copper arsenate (CCA). Due to the toxicity of CCA, the disposal of CCA-treated wood residues is problematic, and burning is considered to provide a solution. The ecotoxicological potential of ash can be high when these components are toxic and mutagenic. The aim of this study was to evaluate the toxicity and genotoxicity of bottom ash leachates originating from CCA-treated wood burning. Physical-chemical analysis of the leachates revealed that in treated wood ashes leachate (CCA-TWBAL), the contents of arsenic and chromium were 59.45 mg.L-1 and 54.28 mg.L-1, respectively. In untreated wood ashes leachate (UWBAL), these contents were 0.70 mg.L-1 and 0.30 mg.L-1, respectively. CCA-TWBAL caused significant toxicity in Lactuca sativa, Allium cepa, and microcrustacean Artemia spp. (LC50 = 12.12 mg.mL-1). Comet assay analyses using NIH3T3 cells revealed that concentrations ranging from 1.0 and 2.5 mg.mL-1 increase the damage frequency (DF) and damage index (DI). According to MTT assay results, CCA-TWBAL at concentrations as low as 1 mg.mL-1 caused a significant decrease in cellular viability. Hemolysis assay analyses suggest that the arsenic and chromium leachate contents are important for the ecotoxic, cytotoxic, and genotoxic effects of CCA-TWBAL.
Assuntos
Antineoplásicos , Arsênio , Eliminação de Resíduos , Animais , Arseniatos/química , Arseniatos/toxicidade , Arsênio/análise , Cromo/análise , Cobre/química , Dano ao DNA , Camundongos , Células NIH 3T3 , Eliminação de Resíduos/métodos , Madeira/químicaRESUMO
Fibromyalgia (FM) is a complex pathology described as persistent hyperalgesia including somatic and mood dysfunctions, depression and anxiety. Although the etiology of FM is still unknown, a significant decrease in biogenic amines is a common characteristic in its pathogenesis. Here, our main objective was to investigate the role of dopamine D3/D2 receptor during the reserpine-induced pain in mice. Our results showed that pramipexole (PPX) - a dopaminergic D3/D2 receptor agonist - inhibited mechanical allodynia and thermal sensitivity induced by reserpine. Relevantly, PPX treatment decreased immobility time and increased the number of grooming in the forced swimming test and splash test, respectively. Animals that received PPX remained longer in the open arms than the reserpine group using elevated plus-maze apparatus. The repeated PPX administration, given daily for 4 days, significantly blocked the mechanical and thermal allodynia during FM model, similarly to pregabalin, although it failed to affect the reserpine-induced thermal nociception. Reserpine administration induced significant downregulation of dopamine concentration in the central nervous system, and repeated treatment with PPX restored dopamine levels in the frontal cortex and spinal cord tissues. Moreover, PPX treatment inhibited oxidants production such as DCFH (2',7'-dichlorodihydrofluorescein) and nitrite, also decreased oxidative damage (carbonyl), and upregulated the activity of superoxide dismutase in the spinal cord. Together, our findings demonstrated the ability of dopamine D3/D2 receptor-preferring agonist in reducing pain and mood dysfunction allied to FM in mice. All experimental protocols were approved by the Universidade Federal de Santa Catarina (UFSC) Ethics Committee (approval No. 2572210218) on May 10, 2018.
RESUMO
Fibromyalgia is a potentially disabling chronic disease, characterized by widespread pain and a range of comorbidities such as hypertension. Among the mechanisms involved in fibromyalgia-like pain symptoms are kinins and their B1 and B2 receptors. Moreover, angiotensin I converting enzyme (ACE) inhibitors, commonly used as antihypertensive drugs, can enhance pain by blocking the degradation of peptides such as substance P and bradykinin, besides enhancing kinin receptors signalling. We investigated the effect of ACE inhibitors on reserpine-induced fibromyalgia-like pain symptoms and the involvement of kinins in this effect in mice. Nociceptive parameters (mechanical and cold allodynia and overt nociception) were evaluated after ACE inhibitors administration in mice previously treated with reserpine. The role of kinin B1 and B2 receptors was investigated using pharmacological antagonism. Additionally, bradykinin levels, as well as the activity of ACE and kininase I, were measured in the sciatic nerve, spinal cord and cerebral cortex of the mice. The ACE inhibitors enalapril and captopril enhanced reserpine-induced mechanical allodynia, and this increase was prevented by kinin B1 and B2 receptor antagonists. Substance P and bradykinin caused overt nociception and increased mechanical allodynia in animals treated with reserpine. Reserpine plus ACE inhibitors increased bradykinin-related peptide levels and inhibited ACE activity in pain modulation structures. Since hypertension is a frequent comorbidity affecting fibromyalgia patients, hypertension treatment with ACE inhibitors in these patients should be reviewed once this could enhance fibromyalgia-like pain symptoms. Thus, the treatment of hypertensive patients with fibromyalgia could include other classes of antihypertensive drugs, different from ACE inhibitors.
Assuntos
Inibidores da Enzima Conversora de Angiotensina/toxicidade , Fibromialgia/induzido quimicamente , Sistema Nervoso/efeitos dos fármacos , Dor Nociceptiva/induzido quimicamente , Limiar da Dor/efeitos dos fármacos , Peptidil Dipeptidase A/metabolismo , Receptores da Bradicinina/metabolismo , Animais , Comportamento Animal/efeitos dos fármacos , Captopril/toxicidade , Modelos Animais de Doenças , Enalapril/toxicidade , Fibromialgia/enzimologia , Fibromialgia/fisiopatologia , Masculino , Camundongos , Sistema Nervoso/enzimologia , Sistema Nervoso/fisiopatologia , Dor Nociceptiva/enzimologia , Dor Nociceptiva/fisiopatologia , Reserpina , Transdução de SinaisRESUMO
Fibromyalgia (FM) is one of the most common musculoskeletal pain conditions. Although the aetiology of FM is still unknown, mitochondrial dysfunction and the overproduction of reactive oxygen intermediates (ROI) are common characteristics in its pathogenesis. The reserpine experimental model can induce FM-related symptoms in rodents by depleting biogenic amines. However, it is unclear whether reserpine causes other pathophysiologic characteristics of FM. So far, no one has investigated the relevance of mitochondrial dysfunction in the reserpine-induced experimental FM model using protection- and insult-based mitochondrial modulators. Reserpine (1 mg/kg) was subcutaneously injected once daily for three consecutive days in male Swiss mice. We carried out analyses of reserpine-induced FM-related symptoms, and their modulation by using mitochondrial insult on ATP synthesis (oligomycin; 1 mg/kg, intraperitoneally) or mitochondrial protection (coenzyme Q10; 150 mg/kg/5 days, orally). We also evaluated the effect of reserpine on mitochondrial function using high-resolution respirometry and oxidative status. Reserpine caused nociception, loss in muscle strength, and anxiety- and depressive-like behaviours in mice that were consistent with clinical symptoms of FM, without inducing body weight and temperature alterations or motor impairment. Reserpine-induced FM-related symptoms were increased by oligomycin and reduced by coenzyme Q10 treatment. Reserpine caused mitochondrial dysfunction by negatively modulating the electron transport system and mitochondrial respiration (ATP synthesis) mainly in oxidative muscles and the spinal cord. These results support the role of mitochondria in mediating oxidative stress and FM symptoms in this model. In this way, reserpine-inducing mitochondrial dysfunction and increased production of ROI contribute to the development and maintenance of nociceptive, fatigue, and depressive-like behaviours.
Assuntos
Fibromialgia/induzido quimicamente , Fibromialgia/patologia , Mitocôndrias/patologia , Reserpina/efeitos adversos , Animais , Comportamento Animal , Depressão/complicações , Depressão/fisiopatologia , Modelos Animais de Doenças , Fadiga/complicações , Fadiga/fisiopatologia , Fibromialgia/fisiopatologia , Masculino , Camundongos , Mitocôndrias/efeitos dos fármacos , Mitocôndrias/metabolismo , Modelos Biológicos , Músculos/efeitos dos fármacos , Músculos/patologia , Nociceptividade/efeitos dos fármacos , Oxirredução , Medula Espinal/efeitos dos fármacos , Medula Espinal/patologia , Ubiquinona/análogos & derivados , Ubiquinona/metabolismoRESUMO
The combination of hyperthermia and chemotherapy has a potential synergic effect in antitumor activity. The development of new biocompatible and biodegradable polymers to simultaneously encapsulate magnetic nanoparticles (MNPs) and antitumoral drugs offer new cancer treatment opportunities. Here, biodegradable and biocompatible poly(thioether-ester) (PTEe) was used to encapsulate MNPs and 4-nitrochalcone (4NC) using miniemulsification and solvent evaporation. The resulting hybrid particles (MNPs-4NC-PTEe) had nanometer-scale diameters, spherical morphology, negative surface charge, high encapsulation efficiency, and superparamagnetic properties. Results showed that 4NC release occurred through diffusion. Free 4NC and MNPs + 4NC-PTEe did not have any cytotoxic effect on erythrocytes and mouse embryonic fibroblast (NIH3T3) cells. 4NC antitumor activity was verified on human cervical cancer (HeLa) and melanoma (B16F10) cells. Cellular uptake of MNPs + 4NC-PTEe nanoparticles was higher in HeLa cells compared to B16F10 and NIH3T3 cells. The hyperthermia application (115 kHz-500 Oe) potentiated the 4NC effects on HeLa and B16F10 cells when MNPs + 4NC-PTEe nanoparticles were used, indicating more effective antitumor activity. We concluded that the use of MNPs + 4NC-PTEe nanoparticles associated with hyperthermia is a promising form of treatment for some types of cancers.
Assuntos
Hipertermia Induzida , Nanopartículas de Magnetita , Nanopartículas , Animais , Ésteres , Fibroblastos , Células HeLa , Humanos , Hipertermia , Camundongos , Células NIH 3T3 , SulfetosRESUMO
Fibromyalgia is characterised mainly by symptoms of chronic widespread pain and comorbidities like depression. Although these symptoms cause a notable impact on the patient's quality of life, the underlying aetiology and pathophysiology of this disease remain incompletely elucidated. The transient receptor potential vanilloid type 1 (TRPV1) is a polymodal receptor that is involved in the development of nociceptive and depressive behaviours, while α-spinasterol, a multitarget TRPV1 antagonist and cyclooxygenase inhibitor, presents antinociceptive and antidepressant effects. The present study investigated the involvement of the TRPV1 channel and the possible effects of α-spinasterol on nociceptive and depressive-like behaviours in an experimental fibromyalgia model. The fibromyalgia model was induced with a subcutaneous (s.c.) injection of reserpine (1 mg/kg) once daily for 3 consecutive days in male Swiss mice. Reserpine administration depleted monoamines and caused mechanical allodynia. This dysfunction was inhibited by SB-366791 (1 mg/kg, oral route [p.o.]), a selective TRPV1 antagonist, with a maximum inhibition (Imax) of 73.4 ± 15.5%, or by the single or 3-day-repeated administration of α-spinasterol (0.3 mg/kg, p.o.), with an Imax of 72.8 ± 17.8% and 78.9 ± 32.9%, respectively. SB-366791 also inhibited the increase of the reserpine-induced immobility time, with an Imax of 100%, while α-spinasterol inhibited this parameter with an Imax of 98.2 ± 21.5% and 100%, by single or repeated administration, respectively. The reserpine-induced mechanical allodynia and the thermal hyperalgesia were abolished by TRPV1-positive fibers desensitization induced by previous resiniferatoxin (RTX) administration. In summary, the TRPV1 channel is involved in the development and maintenance of nociception and depressive-like behaviours in a fibromyalgia model, while the α-spinasterol has therapeutic potential to treat the pain and depression symptoms in fibromyalgia patients.
Assuntos
Fibromialgia/tratamento farmacológico , Hiperalgesia/tratamento farmacológico , Estigmasterol/análogos & derivados , Canais de Cátion TRPV/efeitos dos fármacos , Animais , Antidepressivos/farmacologia , Dor Crônica/tratamento farmacológico , Modelos Animais de Doenças , Masculino , Camundongos , Medição da Dor/efeitos dos fármacos , Qualidade de Vida , Estigmasterol/farmacologia , Canais de Cátion TRPV/metabolismoRESUMO
Fibromyalgia is a disease characterised as generalised chronic primary pain that causes functional disability and a reduction in patients' quality of life, without specific pathophysiology or appropriate treatment. Previous studies have shown that kinins and their B1 and B2 receptors contribute to chronic painful conditions. Thus, we investigated the involvement of kinins and their B1 and B2 receptors in a fibromyalgia-like pain model induced by reserpine in mice. Nociceptive parameters (mechanical allodynia, cold sensitivity and overt nociception) and behaviours of burrowing, thigmotaxis, and forced swimming were evaluated after reserpine administration in mice. The role of kinin B1 and B2 receptors was investigated using knockout mice or pharmacological antagonism. The protein expression of kinin B1 and B2 receptors and the levels of bradykinin and monoamines were measured in the sciatic nerve, spinal cord and cerebral cortex of the animals. Knockout mice for the kinin B1 and B2 receptor reduced reserpine-induced mechanical allodynia. Antagonism of B1 and B2 receptors also reduced mechanical allodynia, cold sensitivity and overt nociception reserpine-induced. Reserpine altered thigmotaxis, forced swimming and burrowing behaviour in the animals; with the latter being reversed by antagonism of kinin B1 receptor. Moreover, reserpine increased the protein expression of kinin B1 and B2 receptors and levels of kinin, as well as reduced the levels of monoamines in peripheral and central structures. Kinins and its B1 and B2 receptors are involved in fibromyalgia-like pain symptoms. B1 or B2 receptors might represent a potential target for the relief of fibromyalgia-like pain symptoms.
Assuntos
Bradicinina/metabolismo , Fibromialgia/metabolismo , Dor/metabolismo , Receptor B1 da Bradicinina/metabolismo , Receptor B2 da Bradicinina/metabolismo , Animais , Comportamento Animal/efeitos dos fármacos , Modelos Animais de Doenças , Fibromialgia/induzido quimicamente , Técnicas de Inativação de Genes , Hiperalgesia/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Nociceptividade/efeitos dos fármacos , Dor/induzido quimicamente , Receptor B1 da Bradicinina/genética , Receptor B2 da Bradicinina/genética , Reserpina/farmacologiaRESUMO
Magnetic nanoparticles encapsulated in biocompatible and biodegradable polymeric matrices are promising materials for biomedical applications, such as transport of antitumoral drugs and cancer treatment by hyperthermia. In this study, biobased poly(thioether-ester), PTEe, was obtained by thiol-ene polymerization and superparamagnetic nanoparticles, MNPs, were successfully incorporated in PTEe nanoparticles by miniemulsification followed by solvent evaporation. MNPs-PTEe nanoparticles with average diameter around 150 nm presented superparamagnetic behavior as confirmed by magnetization curves analysis. MNPs-PTEe nanoparticles did not present hemolytic damage on human red blood cells when incubated for 24 h. According to the cell viability assays, nanoparticles did not present any cytotoxic effect on murine fibroblast cell (NIH3T3) and human cervical cancer (HeLa). Hyperthermia assays were applied, demonstrating that AC magnetic field application (110 KHz-500 Oe) for 20 min significantly reduced the cells viability. The morphology evaluation of HeLa showed a hypoxia region one hour after hyperthermia application. Therefore, the results indicated that the superparamagnetic poly(thioether-ester) nanoparticles can be an excellent alternative for the targeted delivery of antitumor drugs and cancer treatment for hyperthermia.